|
Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer. |
|
|
Honoraria - AstraZeneca; Pfizer |
Consulting or Advisory Role - AstraZeneca/MedImmune; Clovis Oncology; Pfizer; Roche |
Research Funding - AstraZeneca (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Roche (Inst) |
Research Funding - AstraZeneca (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche |
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Celldex (Inst) |
|
|
|
Consulting or Advisory Role - Amgen; Clovis Oncology; Immunovaccine; Verastem |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Merck (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
|
Michelle Margaret Vaughan |
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Pfizer |
Consulting or Advisory Role - AstraZeneca; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |